EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access

Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial

Vishal R Dhere, David M Schuster, Subir Goyal, Eduard Schreibmann, Bruce W Hershatter, Sagar A Patel, Joseph W Shelton, Sheela Hanasoge, Pretesh R Patel, Nikhil T Sebastian, Omotayo A Adediran, Ismaheel O Lawal und 1 weitere

Practical Radiation Oncology · 2024

DOI: 10.1016/j.prro.2024.05.011 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Practical Radiation Oncology, 2024. Verfasst von Vishal R Dhere und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. Electronic address: vdhere@emory.edu. Hauptthemen laut MEDLINE: Carboxylic Acids, Cyclobutanes, Prostatectomy, Prostatic Neoplasms. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Emory University, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Whole-pelvis (WP) radiation therapy (radiation) improved biochemical relapse-free survival (bRFS) compared with prostate bed (PB)-only radiation in the Radiation Therapy Oncology Group 0534, but was performed in an era prior to positron emission tomography (PET) staging. Separately, 18F-fluciclovine PET/CT-guided postprostatectomy radiation improved 3-year bRFS versus radiation guided by conventional imaging alone. We hypothesized that patients who were changed from WP to PB-only radiation after PET would have bRFS that was: (a) no higher than patients initially planned for PB-only radiation; and (b) lower than patients planned for WP radiation without PET guidance. METHODS AND MATERIALS: We conducted a post hoc analysis of a prospective, randomized trial comparing conventional (arm 1) versus PET-guided (arm 2) postprostatectomy radiation. In arm 2, pre-PET treatment field decisions were recorded and post-PET fields were defined per protocol; pathologic node negative (pN0) without pelvic or extrapelvic PET uptake received PB-only radiation. Three-year bRFS was compared in patients planned for WP with change to PB-only radiation (arm 2 [WP:PB]) vs arm 2 patients planned for PB-only with final radiation to PB-only (arm 2 [PB:PB]) and arm 1 pN0 patients treated with WP radiation (arm 1 [WP]) using the Z test and log-rank test. Demographics were compared using the chi-square test, Fisher exact test, or analysis of variance, as appropriate. RESULTS: We identified 10 arm 2 (WP:PB), 31 arm 2 (PB:PB) and 11 arm 1 (WP) patients. Androgen deprivation was used in 50.0% of arm 2 (WP:PB) and 3.2% of arm 2 (PB:PB) patients, P < .01. Median preradiation prostate-specific antigen was higher in arm 2 (WP:PB) vs arm 2 (PB:PB) patients (0.4 vs 0.2 ng/mL, P = .03); however, there were no significant differences in T stage, Gleason score, or margin positivity. Three-year bRFS was 80% in arm 2 (WP:PB) vs 87.4% in arm 2 (PB:PB), P = .47, respectively. Arm 1(WP) patients had significantly worse 3-year (23%) bRFS vs arm 2 (WP:PB), P < .01. CONCLUSIONS: Patients initially planned for WP radiation with field decision change to PB-only radiation after PET showed (1) no significant difference in 3-year bRFS compared with patients initially planned for PB-only radiation; and (2) improved bRFS compared with patients receiving WP radiation without PET guidance. PET-guided volume de-escalation in selected patients may be 1 approach to mitigating toxicity without compromising outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carboxylic AcidsCyclobutanesProstatectomyProstatic NeoplasmsAgedHumansMaleMiddle AgedDisease-Free SurvivalNeoplasm Recurrence, LocalPositron Emission Tomography Computed TomographyProspective Studies

Substanzen

Carboxylic AcidsCyclobutanesfluciclovine F-18

Autor:innen und Institutionen

  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. Electronic address: vdhere@emory.edu.
  • Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
  • Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia.
  • Department of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Förderung

  • NCI NIH HHS
  • Emory University
  • NIH
  • Amgen
  • FUJIFILM Pharmaceuticals U.S.A.
  • Blue Earth Diagnostics

Zitieren

APA

Dhere, V. R., Schuster, D. M., Goyal, S., Schreibmann, E., Hershatter, B. W., Patel, S. A., Shelton, J. W., Hanasoge, S., Patel, P. R., Sebastian, N. T., Adediran, O. A., Lawal, I. O., & Jani, A. B. (2024). Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial. Practical Radiation Oncology. https://doi.org/10.1016/j.prro.2024.05.011

Vancouver

Dhere VR, Schuster DM, Goyal S, Schreibmann E, Hershatter BW, Patel SA, et al. Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial. Practical Radiation Oncology. 2024. doi:10.1016/j.prro.2024.05.011

BibTeX
@article{Dhere2024,
  author = {Dhere, Vishal R and Schuster, David M and Goyal, Subir and Schreibmann, Eduard and Hershatter, Bruce W and Patel, Sagar A and Shelton, Joseph W and Hanasoge, Sheela and Patel, Pretesh R and Sebastian, Nikhil T and Adediran, Omotayo A and Lawal, Ismaheel O and Jani, Ashesh B},
  title = {Biochemical Relapse-Free Survival in Postprostatectomy Patients Receiving 18F-Fluciclovine-Guided Prostate Bed-Only Radiation: Post Hoc Analysis of a Prospective Randomized Trial},
  journal = {Practical Radiation Oncology},
  year = {2024},
  doi = {10.1016/j.prro.2024.05.011}
}
Kostenlos starten →